Acadia Pharmaceuticals Logo
US0042251084
603035
ACAD

Acadia Pharmaceuticals

Loading quotes...

Forecast

The analysts' average price target is €27.31 (+66.73%). The median is €29.99 (+83.09%).

Buy
  25
Hold
  11
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit

    A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » More on de.investing.com


  • Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference

    At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » More on de.investing.com


  • Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results

    Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » More on de.investing.com


  • FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin

    The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » More on de.investing.com


  • Acadia Pharmaceuticals insider sells nearly half of direct holdings

    James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026—about 46.6% of his direct holdings—at a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » More on finance.yahoo.com

Financials

In the last quarter, Acadia Pharmaceuticals had revenue of €302.19m and net profit of €47.25m
(EUR) September 2026
YoY
Revenue 302.19m 27.28%
Gross profit 271.21m 23.85%
Net profit 47.25m 22.74%
EBITDA 71.02m 75.28%

Fundamentals

Metric Value
Market capitalization
€2.94bn
Number of shares
172.83m
52-week high/low
€28.13 - €14.41
Dividends No
Beta
0.89
P/E ratio
8.80
PEG ratio
0.24
P/B ratio
2.33
P/S ratio
2.70

Company profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Name
Acadia Pharmaceuticals
CEO
Catherine E. Owen Adams
Headquarters San Diego, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
27/05/2004
Employees 797

Ticker symbols

Exchange Symbol
NASDAQ
ACAD
Frankfurt
DR6.F
DĂŒsseldorf
DR6.DU
London
0A4W.L
SIX
DR6.SW
MĂŒnchen
DR6.MU
đŸȘ

Parqet  uses cookies. Learn more